Ascendis Pharma A/S (BVMF:A1SN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 68.09B |
| Revenue (ttm) | 4.66B +98.0% |
| Net Income | -1.47B |
| EPS | -24.33 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 44.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50 |
| Average Volume | 262 |
| Open | 76.05 |
| Previous Close | 78.57 |
| Day's Range | 76.05 - 76.05 |
| 52-Week Range | 53.79 - 78.57 |
| Beta | 0.49 |
| RSI | 57.32 |
| Earnings Date | Apr 30, 2026 |
About Ascendis Pharma
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Con...
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq...
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq f...
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia
- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability pr...
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated wi...
Ascendis Pharma Transcript: TD Cowen 46th Annual Health Care Conference
YUVIWEL is set for a U.S. launch in early Q2 following FDA approval, targeting both untreated and switch patients with a differentiated weekly dosing profile and strong safety data. Pricing will reflect its clinical benefits, and international expansion is planned.
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annu...
Ascendis Pharma Transcript: FDA announcement
YUVIWEL received FDA approval as the first once-weekly therapy for children with achondroplasia, showing significant efficacy and safety in clinical trials. Commercial launch is planned for early Q2 2026, with label expansion and international rollout to follow.
Ascendis wins U.S. approval for therapy for children with dwarfism
The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerate...
Ascendis Pharma Earnings Call Transcript: Q4 2025
Strong 2025 performance with EUR 720M revenue, led by YORVIPATH and SKYTROFA growth, supports a robust outlook for 2026. Pipeline advances, global launches, and a solid cash position underpin targets of EUR 500M operating cash flow in 2026 and EUR 5B annual revenue by 2030.
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a...
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday...
Ascendis Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
2025 revenue reached $1.86B, with strong cash reserves and no major debt. Elevidys and PMOs drive growth, while next-gen siRNA pipeline advances. Focus in 2026 is on expanding Elevidys access, early intervention, and progressing key R&D milestones.
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascen...
Ascendis Pharma Transcript: Study Update
The phase 2 Coach trial in children with Achondroplasia showed that combining TransCon CNP and Growth Hormone led to unprecedented annualized growth velocities, significant improvements in body proportionality and arm span, and a strong safety profile. These results set a new efficacy benchmark and support advancing to phase 3 trials.
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-p...
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference ...
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
The Investment Committee give you their top stocks to watch for the second half.
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasi...
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announ...